ClavystBio
ClavystBio is a Singapore-based life sciences investor and venture builder, wholly owned by Temasek, that identifies, incubates, and funds biotech, medtech, and digital health companies from Singapore's academic and translational research pipeline.
- Company typePrivate
- Founded2022
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingServices
What ClavystBio does
ClavystBio is a Singapore-based life sciences investor and venture builder established by Temasek in 2022 to translate Singapore-origin biotech, medtech, and digital health research into globally competitive companies. The firm operates three core programs: a Venture Builder function that identifies and incubates new companies; a Trusted Partner function that forges public-private partnerships (notably with A*STAR, NUS, Duke-NUS, NHIC's CADRE program, and SEEDS Capital); and a physical ecosystem asset, Node 1, a collaborative innovation space at Science Park 1 that hosts ventures graduating from incubators. Through 65LAB, a company-creation vehicle co-founded with Evotec SE and backed by Lightstone Ventures, Leaps by Bayer, and Polaris Partners, ClavystBio funds Singapore academic projects up to US$1.5M each over 18–24 months with the goal of spinning off new companies within 3–5 years.
The portfolio spans 21 named companies across modalities including AAV gene therapy (Nuevocor, Cirrus Therapeutics), multi-payload ADCs (Callio Therapeutics), precision biotherapeutics (Hummingbird Bioscience, Engine Biosciences), cellular therapy (MediSix Therapeutics), bat-biology-derived therapeutics (Paratus Sciences), robotic surgical systems (Biobot Surgical), AI patient monitoring (Respiree), and autophagy-based protein degradation (Automera). Several portfolio companies have achieved FDA, CE, or IND regulatory milestones. The firm also operates a cross-border collaboration with Biosparc (a Temasek/Suzhou Industrial Park life sciences industrial park launching in 2026) and True Light PE to support China-Singapore R&D. Revenue mechanics derive from management fees on funds under management, carried interest on portfolio exits, and modest ecosystem services income from Node 1; specific revenue figures are not publicly disclosed.
ClavystBio firmographics
Firmographics- Name
- ClavystBio
- Legal name
- ClavystBio Pte Ltd
- Website
- https://clavystbio.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ClavystBio is a Singapore-based life sciences investor and venture builder, wholly owned by Temasek, that identifies, incubates, and funds biotech, medtech, and digital health companies from Singapore's academic and translational research pipeline.
- Ownership category
- akta.pro rank
Where ClavystBio is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices1 record
Markets served
ClavystBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Others
Revenue model
- Venture Capital Returns (Carry and Management Fees): As a life sciences investor and venture builder established by Temasek, ClavystBio generates returns through carried interest on portfolio company exits and management fees on funds under management. It is positioned as a long-term profit-seeking investor targeting a tripling of returns from biotechnology investments.
- Ecosystem Services: ClavystBio provides Node 1 collaborative workspace and ecosystem convening services to support portfolio and community companies, charging rent and providing shared lab infrastructure, meeting spaces, and operational support.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
ClavystBio product offering
Product offeringCore offering
ClavystBio is a life sciences investor and venture builder that deploys equity capital and operational support to launch and grow early-stage biotech, medtech, and digital health companies from Singapore. It provides venture building services through active incubation, the 65LAB company creation partnership with Evotec and global investors, the Node 1 collaborative innovation space, and partnership facilitation with Singapore's research institutions and government agencies.
Product overview
ClavystBio is a life sciences investor and venture builder established by Temasek, committed to launching and growing global companies from Singapore. The company operates through venture building services, strategic partnerships, and its collaborative innovation space Node 1. Core offerings include identification and incubation of promising life sciences innovations through 65LAB (a partnership with Evotec and global investors), investment and growth capital deployment, partnership facilitation with academic institutions and industry, and provision of lab infrastructure at Node 1. The portfolio encompasses therapeutics companies (Nuevocor with gene therapy for cardiomyopathies, Cirrus Therapeutics with AAV ocular gene therapy, Callio Therapeutics with multi-payload ADCs, Hummingbird Bioscience with precision biotherapeutics), MedTech/Digital Health companies (Biobot Surgical with robotic surgical systems, Respiree with AI-powered 1Bio disease management platform), and enabling infrastructure companies (NSG BioLabs with shared lab facilities).
Differentiator
Problem solved
Functional benefit
Brands
- Node 1: Collaborative innovation space for life sciences ventures that have graduated from incubators, offering private suites, graduation spaces, operational support, and community access
- 65LAB
- Biosparc
Products and services
- Venture Builder Services
- Trusted Partner Services
- Node 1
- 65LAB
Quantifiable outcome
- Multiple portfolio companies achieved major regulatory milestones including FDA 510(k) clearance, IND clearance, and CE marking
- +1 more outcomes
Companies that use ClavystBio
Customer profileSegments3 records
Ideal customer profiles3 records
ClavystBio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature1 record
ClavystBio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and secondary.
- A*STAR (Agency for Science, Technology and Research)coreClavystBio and A*STAR signed a two-year MoU to create and grow MedTech ventures in Singapore. The partnership co-creates new ventures from research, advances MedTech product development through MedTech Catapult and DxD Hub national initiatives, accelerates commercial readiness in diagnostics and digital health, and strengthens Singapore's MedTech ecosystem. The partnership leverages ClavystBio's venture investing and industry relationships alongside A*STAR's deep scientific expertise and productisation platforms.
- 65LAB (Evotec, Lightstone Ventures, Leaps by Bayer, Polaris Partners)core65LAB is a unique company creation vehicle co-founded by Lightstone Ventures and Evotec SE, with ClavystBio, Leaps by Bayer, Polaris Partners, and Polaris Innovation Fund as investor partners. It identifies promising academic research from A*STAR, NUS, and Duke-NUS Medical School, provides up to US$1.5 million in project funding over 18-24 months, and evaluates successful projects for further investment and new company formation. Evotec contributes its end-to-end R&D platform and Expert-in-Residence support. 65LAB is the first collaboration of its kind in Singapore and Asia.
- Biosparc (Temasek / Suzhou Industrial Park)secondaryA tripartite strategic collaboration between Biosparc, ClavystBio, and True Light PE to support innovators from both China and Singapore in advancing research, clinical development, and early commercialization. The partnership leverages each party's networks and capabilities to strengthen cross-border R&D and establish a pipeline for project landing and growth. Biosparc is a life sciences industrial park on Sangtian Science Island in Suzhou, under development with an expected launch in 2026.
- NHIC (National Health Innovation Centre Singapore)secondaryClavystBio is a partner of NHIC's CADRE (Clinical Advancement and Development for Research, Entrepreneurship and Enterprise) programme. NHIC works with Public Health Institutions across Singapore to identify and commercialize promising clinical innovations. ClavystBio supports healthtech projects with Public Healthcare Clusters in early-stage commercialization through venture co-creation, technology development, co-investment, and nurturing of tri-competent healthtech talent.
Scale indicators5 records
Recent moves9 records
Expansion highlights6 records
ClavystBio competitors and assessment
Company assessmentDirect peers
- Baker Bros. Advisors: Biotech-focused investment advisor with deep, concentrated positions in clinical-stage life sciences companies — comparable long-duration, fundamentals-driven life sciences investment orientation.
- Flagship Pioneering: The closest peer: a biotech venture creation firm that originates and builds new companies from scientific research, with active incubation and dedicated operating support — directly mirrors ClavystBio's venture builder model.
- ARCH Venture Partners: Long-standing biotech-focused VC that partners with founders to build companies from breakthrough science across therapeutics and platforms — directly comparable investment mandate and capital scale.
- Polaris Partners: Biotech and healthcare VC that co-invests in ClavystBio's 65LAB programme and runs its own venture creation activities — directly comparable life sciences focus and co-investment profile.
- OrbiMed: Healthcare-dedicated investment firm spanning venture, growth, and public equities across therapeutics, medical devices, and diagnostics — directly comparable life sciences investment focus.
- Atlas Venture: Biotech-focused VC that actively creates, builds, and funds new life sciences companies from inception through exit — operates a venture creation model analogous to ClavystBio's 65LAB.
- 5AM Ventures: Early-stage life sciences VC that creates and funds biotech companies from academic and startup-stage science — comparable early-stage biotech venture creation model.
- RA Capital Management: Dedicated life sciences investment firm running a crossover fund that supports biotech companies from formation through IPO — comparable institutional life sciences investment model.
- Leaps by Bayer: Bayer's life sciences venture arm investing in breakthrough biotech, medtech, and digital health — co-invests in ClavystBio's 65LAB and shares a venture-stage life sciences investment mandate.
- Andreessen Horowitz (a16z Bio): Tech-rooted VC with a dedicated Bio fund investing across biotech, digital health, and healthcare infrastructure — comparable in its active partnership approach and breadth across life sciences sub-sectors.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ClavystBio social profiles
Digital presenceClavystBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
ClavystBio leadership team
Management profileNumber of profiles
Profiles6 records
ClavystBio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ClavystBio M&A and investment
M&A and investmentM&A
Investments17 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ClavystBio
What does ClavystBio do?
ClavystBio is a life sciences investor and venture builder that deploys equity capital and operational support to launch and grow early-stage biotech, medtech, and digital health companies from Singapore. It provides venture building services through active incubation, the 65LAB company creation partnership with Evotec and global investors, the Node 1 collaborative innovation space, and partnership facilitation with Singapore's research institutions and government agencies.
Is ClavystBio a public or private company?
ClavystBio is a private company. It is classified as corporate owned and is currently operating.
When was ClavystBio founded?
ClavystBio was founded in 2022. It employs 11 to 50 people.
Where is ClavystBio based?
ClavystBio is headquartered in Singapore, Singapore, in the Asia region.
How does ClavystBio make money?
Two revenue lines are on record. Venture Capital Returns (Carry and Management Fees) is the primary driver. The others are ecosystem Services.
Who are ClavystBio's main competitors?
Direct peers on record are Baker Bros. Advisors, Flagship Pioneering, ARCH Venture Partners, Polaris Partners, OrbiMed, Atlas Venture, 5AM Ventures, RA Capital Management, Leaps by Bayer and Andreessen Horowitz (a16z Bio).
Does ClavystBio have an API?
No public API is recorded for ClavystBio.